Showing 4981-4990 of 7161 results for "".
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.
- Zocdoc Highlights The Year in Skincarehttps://practicaldermatology.com/news/zocdoc-highlights-the-year-in-skincare/2461206/Dermatology consultation and follow-up appointments increased by 16 percent from January-April 2021 to January-April 2022, and while many American patients and dermatologists turned to telehealth as a
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- Three Beliefs Affect Older Adults Sunscreen Usehttps://practicaldermatology.com/news/three-beliefs-affect-older-adults-sunscreen-use/2461202/Reminders from a romantic partner might be an effective way to encourage sunscreen use by people age 50 or older, suggests a study in the May/June issue of The Journal of the Dermatology Nurses' Association. People older than 50 are also more likely to use su
- Aspiring Physician with Psoriasis Among AbbVie Scholarship Recipientshttps://practicaldermatology.com/news/aspiring-dermatologist-with-psoriasis-among-abbvie-scholarship-recipients/2461201/AbbVie has awarded 45 scholarships as part of its 2022-2023 AbbVie Immunology Scholarship program. The program, which provides financial support to students living with chronic, immune-mediated diseases pursuing higher education in the United States, received more than 1,000 applic
- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician
- Almirall and Inserm Transfert Collaborate to Develop Innovative Treatments for Vitiligohttps://practicaldermatology.com/news/almirall-and-inserm-transfert-collaborate-to-develop-innovative-treatments-for-vitiligo/2461198/Almirall, S.A. and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have entered into a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership, signed by
- Barbie Launches Ken Doll with Vitiligohttps://practicaldermatology.com/news/barbie-launches-ken-doll-with-vitiligo/2461197/Mattel, the parent company for Barbie, will include a Ken doll with vitiligo as part of their 2022 Fashionistas line. The Barbie Fashionistas line includes Barbie dolls with more variety of skin tones, eye colors, hair colors and textures, body types, disabilities, and fashions.
- Eucerin Launches Skin-focused Sun Care Line in the UShttps://practicaldermatology.com/news/eucerin-launches-skin-focused-sun-care-line-in-the-us/2461196/Eucerin is expanding into the US sun protection market with its new Eucerin Sun line. Developed with dermatologists and consisting of seven products across face and body, Eucerin Sun is formulated with a five antioxidants to go beyond sun protection and help promote healthy-looking
- FDA Issues Complete Response Letter for UCB's Bimekizumabhttps://practicaldermatology.com/news/fda-issues-complete-response-letter-for-ucbs-bimekizumab/2461195/There’s a delay in the US regulatory review of UCB’s bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. FDA has indicated it cannot approve the BLA for bimekizumab in its current form. The agency issued a Complete Response Letter (CRL) that sta